Aug 12, 2026 06:00AM
Jul 11, 2024 11:46AM
Oct 17, 2023 08:00AM
Sep 19, 2023 08:00AM
Sep 19, 2023 08:00AM
Sep 18, 2023 07:01AM
Sep 18, 2023 07:00AM Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Sep 7, 2023 09:01AM
Sep 7, 2023 09:00AM
Aug 14, 2023 08:30AM
Jun 6, 2023 08:30AM
Jun 1, 2023 09:10AM
May 24, 2023 08:03AM
May 24, 2023 08:00AM Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
May 15, 2023 04:30PM
May 2, 2023 08:04AM
May 2, 2023 08:00AM
May 2, 2023 08:00AM
Apr 3, 2023 08:00AM
Apr 3, 2023 08:00AM
Mar 28, 2023 04:45PM Eloxx Pharmaceuticals (ELOX) Announces Submission of IND Application for ZKN-013
Mar 28, 2023 04:45PM
Mar 28, 2023 04:45PM
Feb 27, 2023 04:05PM
Feb 27, 2023 04:05PM
Jan 25, 2023 08:00AM
Jan 25, 2023 08:00AM
Dec 1, 2022 08:45AM Eloxx Pharmaceuticals (ELOX) Announces Reverse Stock Split Effective
Dec 1, 2022 08:45AM
Dec 1, 2022 08:45AM
Nov 10, 2022 05:15PM
Nov 10, 2022 05:15PM
Nov 1, 2022 04:30PM
Nov 1, 2022 04:30PM
Sep 14, 2022 04:07PM Eloxx Pharmaceuticals (ELOX) Phase 2 Combination Clinical Trial of ELX-02 in Class 1 CF Patients Did Not Achieve Statistical Significance for Efficacy
Sep 14, 2022 04:05PM
Sep 14, 2022 04:05PM
Sep 14, 2022 04:05PM
Aug 15, 2022 08:00AM
Aug 15, 2022 08:00AM
Jul 5, 2022 08:00AM
Jul 5, 2022 08:00AM Eloxx Pharmaceuticals Announces Changes to Board of Directors
May 10, 2022 08:00AM
May 10, 2022 08:00AM
Mar 31, 2022 07:00AM
Mar 31, 2022 07:00AM
Mar 29, 2022 07:00AM
Mar 29, 2022 07:00AM
Nov 17, 2021 07:00AM Eloxx Pharmaceuticals (ELOX) Announces Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02
Nov 17, 2021 07:00AM

328,342 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All